Published in J Clin Oncol on September 01, 1999
Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol (2011) 7.24
Adherence to ESMO clinical recommendations for prophylaxis of chemotherapy-induced nausea and vomiting. Support Care Cancer (2011) 2.21
Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings. Support Care Cancer (2006) 1.98
The 5-HT3 receptor as a therapeutic target. Expert Opin Ther Targets (2007) 1.86
Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. Br J Cancer (2006) 1.54
Chemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based study. Support Care Cancer (2011) 1.52
5-Hydroxytryptamine-receptor antagonists versus prochlorperazine for control of delayed nausea caused by doxorubicin: a URCC CCOP randomised controlled trial. Lancet Oncol (2005) 1.43
The impact of chemotherapy-induced nausea and vomiting on health-related quality of life. Support Care Cancer (2006) 1.41
Assessing the impact of chemotherapy-induced nausea and vomiting on patients' daily lives: a modified version of the Functional Living Index-Emesis (FLIE) with 5-day recall. Support Care Cancer (2003) 1.36
The impact of cancer research: how publications influence UK cancer clinical guidelines. Br J Cancer (2008) 1.31
Chemotherapy-induced nausea and vomiting in routine practice: a European perspective. Support Care Cancer (2004) 1.30
Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT 3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response. Support Care Cancer (2006) 1.30
Insight in the prediction of chemotherapy-induced nausea. Support Care Cancer (2009) 1.28
A prospective observational study of chemotherapy-related nausea and vomiting in routine practice in a UK cancer centre. Support Care Cancer (2007) 1.27
Chemotherapy-induced nausea and vomiting in clinical practice: impact on patients' quality of life. Support Care Cancer (2012) 1.20
Stability of an extemporaneous oral liquid aprepitant formulation. Support Care Cancer (2008) 1.13
Pooled analysis of phase III clinical studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV). Support Care Cancer (2013) 1.12
Fosaprepitant and aprepitant: an update of the evidence for their place in the prevention of chemotherapy-induced nausea and vomiting. Core Evid (2010) 1.09
Delayed emesis: moderately emetogenic chemotherapy. Support Care Cancer (2004) 1.06
Palonosetron plus 3-day aprepitant and dexamethasone to prevent nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer (2010) 1.05
Treating nausea and vomiting in palliative care: a review. Clin Interv Aging (2011) 1.04
Incidence of chemotherapy-induced nausea and vomiting in Taiwan: physicians' and nurses' estimation vs. patients' reported outcomes. Support Care Cancer (2005) 1.03
One third of patients with radiotherapy-induced nausea consider their antiemetic treatment insufficient. Support Care Cancer (2008) 1.00
Platinum drugs in the treatment of non-small-cell lung cancer. Br J Cancer (2002) 1.00
Daily palonosetron is superior to ondansetron in the prevention of delayed chemotherapy-induced nausea and vomiting in patients with acute myelogenous leukemia. Cancer (2010) 0.98
Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer. Support Care Cancer (2007) 0.95
Cannabinoids for pain and nausea. BMJ (2001) 0.94
Potential synergism between hypnosis and acupuncture—is the whole more than the sum of its parts? Evid Based Complement Alternat Med (2006) 0.92
Acute emesis: moderately emetogenic chemotherapy. Support Care Cancer (2004) 0.90
Serum tumor markers in pediatric osteosarcoma: a summary review. Clin Sarcoma Res (2012) 0.90
Biweekly docetaxel, cisplatin, and 5-fluorouracil (DCF) chemotherapy for advanced esophageal squamous cell carcinoma: a phase I dose-escalation study. Cancer Chemother Pharmacol (2010) 0.90
Cost-effectiveness analysis of aprepitant in the prevention of chemotherapy-induced nausea and vomiting in Belgium. Support Care Cancer (2007) 0.89
Antiemetic therapy options for chemotherapy-induced nausea and vomiting in breast cancer patients. Breast Cancer (Dove Med Press) (2011) 0.86
The importance of clinical practice guidelines (CPGs) for the quality and development of supportive care in Central and Eastern European (CEE) countries. Support Care Cancer (2003) 0.84
Multicenter, randomized trial of ramosetron plus dexamethasone versus ramosetron alone in controlling cisplatin-induced emesis. Support Care Cancer (2003) 0.84
Acupuncture and acupressure for the prevention of chemotherapy-induced nausea--a randomised cross-over pilot study. Support Care Cancer (2006) 0.84
Phase II study of biweekly plitidepsin as second-line therapy for advanced or metastatic transitional cell carcinoma of the urothelium. Mar Drugs (2009) 0.83
Chemotherapy-Induced Nausea and Vomiting: Time for More Emphasis on Nausea? Oncologist (2015) 0.83
Radiotherapy-induced nausea and vomiting (RINV): antiemetic guidelines. Support Care Cancer (2004) 0.83
Current position of 5HT3 antagonists and the additional value of NK1 antagonists; a new class of antiemetics. Br J Cancer (2003) 0.83
Adherence to antiemetic guidelines in patients with malignant glioma: a quality improvement project to translate evidence into practice. Support Care Cancer (2014) 0.83
Aprepitant as salvage antiemetic therapy in breast cancer patients receiving doxorubicin and cyclophosphamide. Support Care Cancer (2008) 0.83
Aprepitant plus granisetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients with gastric cancer treated with S-1 plus cisplatin. J Gastroenterol (2013) 0.83
Patient- and treatment-related risk factors for nausea and emesis during concurrent chemoradiotherapy. Strahlenther Onkol (2010) 0.82
Nausea and emesis: still an unsolved problem in cancer patients? Support Care Cancer (2002) 0.82
Low-dose granisetron for prophylaxis of acute chemotherapy-induced nausea and vomiting: a pilot study. Support Care Cancer (2005) 0.81
Systemic treatment-induced gastrointestinal toxicity: incidence, clinical presentation and management. Ann Gastroenterol (2012) 0.81
Phase I clinical and pharmacokinetic study of trabectedin and carboplatin in patients with advanced solid tumors. Invest New Drugs (2010) 0.81
A double-blind, crossover, randomized dose-comparison trial of granisetron for the prevention of acute and delayed nausea and emesis in children receiving moderately emetogenic carboplatin-based chemotherapy. Support Care Cancer (2007) 0.81
Antiemetic prescription in Italian breast cancer patients submitted to adjuvant chemotherapy. Support Care Cancer (2003) 0.81
Emetic potential of daily oral etoposide. Support Care Cancer (2006) 0.81
Factors associated with weight loss during radiotherapy in patients with stage I or II head and neck cancer. Support Care Cancer (2011) 0.81
Comparison of two dosing schedules of palonosetron for the prevention of nausea and vomiting due to interleukin-2-based biochemotherapy. Support Care Cancer (2012) 0.80
Systemic therapy for cervical cancer with potentially regulatable oncolytic adenoviruses. PLoS One (2008) 0.80
Using aprepitant as secondary antiemetic prophylaxis for cancer patients with cisplatin-induced emesis. Support Care Cancer (2011) 0.80
A pilot study of ondansetron plus metopimazine vs. ondansetron monotherapy in children receiving highly emetogenic chemotherapy: a Bayesian randomized serial N-of-1 trials design. Support Care Cancer (2005) 0.79
Randomized double-blind study of the Reliefband as an adjunct to standard antiemetics in patients receiving moderately-high to highly emetogenic chemotherapy. Support Care Cancer (2003) 0.79
Factors influencing the choice of 5-HT3-receptor antagonist antiemetics: focus on elderly cancer patients. Support Care Cancer (2004) 0.79
The 2004 Perugia Antiemetic Consensus Guideline process: methods, procedures, and participants. Support Care Cancer (2004) 0.79
Aprepitant: the evidence for its place in the prevention of chemotherapy-induced nausea and vomiting. Core Evid (2007) 0.79
Assessing prescribing patterns for the prevention of chemotherapy-induced nausea and vomiting in the national center for cancer care and research. Saudi Pharm J (2015) 0.79
A feasibility study of outpatient chemotherapy with S-1 + cisplatin in patients with advanced gastric cancer. Gastric Cancer (2012) 0.78
Is there a need to identify new anti-emetic drugs? Drug Discov Today Ther Strateg (2007) 0.78
Treatment of non-pain-related symptoms. Cancer J (2013) 0.78
Emesis induced by low or minimal emetic risk chemotherapy. Support Care Cancer (2004) 0.78
Granisetron versus tropisetron for prophylaxis of acute chemotherapy-induced emesis: a pooled analysis. Support Care Cancer (2004) 0.78
Gynecologic malignancy in pregnancy. Obstet Gynecol Sci (2013) 0.78
A feasibility study of postoperative chemotherapy with S-1 and cisplatin (CDDP) for stage III/IV gastric cancer (CCOG 1106). Gastric Cancer (2014) 0.78
A Phase II single-arm trial of palonosetron for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in malignant glioma patients receiving multidose irinotecan in combination with bevacizumab. Ther Clin Risk Manag (2016) 0.78
Implementation of institutional antiemetic guidelines for low emetic risk chemotherapy with docetaxel: a clinical and cost evaluation. Support Care Cancer (2011) 0.77
Filling in the gaps: reporting of concurrent supportive care therapies in breast cancer chemotherapy trials. Support Care Cancer (2011) 0.77
Midazolam for acute emesis refractory to dexamethasone and granisetron after highly emetogenic chemotherapy: a phase II study. Support Care Cancer (2005) 0.77
Economic disparities in treatment costs among ambulatory Medicaid cancer patients. J Natl Med Assoc (2004) 0.77
Docetaxel plus cisplatin is effective for patients with metastatic breast cancer resistant to previous anthracycline treatment: a phase II clinical trial. BMC Cancer (2005) 0.77
The cost of chemotherapy-induced nausea and vomiting in Italy. Support Care Cancer (2006) 0.77
A phase II, randomized study of aprepitant in the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapies in colorectal cancer patients. Mol Clin Oncol (2015) 0.77
An assessment of chemotherapy-induced nausea and vomiting direct costs in three EU countries. Drugs Context (2015) 0.77
Ondansetron treatment in a child presenting with chronic intractable pruritus. Pain Res Manag (2006) 0.77
Nausea as a sentinel symptom for cytotoxic chemotherapy effects on the gut-brain axis among women receiving treatment for recurrent ovarian cancer: an exploratory analysis. Support Care Cancer (2016) 0.77
Randomized study of dexamethasone treatment for delayed emesis, anorexia and fatigue induced by irinotecan. Support Care Cancer (2003) 0.76
Phase II trial of neoadjuvant chemotherapy with docetaxel, nedaplatin, and S1 for advanced esophageal squamous cell carcinoma. Cancer Sci (2016) 0.76
2016 updated MASCC/ESMO consensus recommendations: Prevention of acute chemotherapy-induced nausea and vomiting in children. Support Care Cancer (2016) 0.76
Chemotherapy for breast cancer in pregnancy: evidence and guidance for oncologists. Ther Adv Med Oncol (2011) 0.76
Antiemetics in children receiving chemotherapy. Support Care Cancer (2004) 0.75
Control of chemotherapy-induced nausea in patients receiving outpatient cancer chemotherapy. Int J Clin Oncol (2015) 0.75
Breast cancer in pregnancy: a literature review. Facts Views Vis Obgyn (2009) 0.75
Palonosetron versus older 5-HT3 receptor antagonists for nausea prevention in patients receiving chemotherapy: a multistudy analysis. J Community Support Oncol (2014) 0.75
Use and cardiovascular safety of transdermal and other granisetron preparations in cancer management. Cancer Manag Res (2013) 0.75
Evaluation of the efficacy of palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with gastric cancer treated with S-1 plus cisplatin. Int J Clin Oncol (2015) 0.75
Prevention of chemotherapy-induced nausea and vomiting: focus on fosaprepitant. Ther Clin Risk Manag (2008) 0.75
Phase II trial of biweekly docetaxel, cisplatin, and 5-fluorouracil chemotherapy for advanced esophageal squamous cell carcinoma. Cancer Chemother Pharmacol (2016) 0.75
Combination of Aprepitant, Azasetron, and Dexamethasone as Antiemetic Prophylaxis in Women with Gynecologic Cancers Receiving Paclitaxel/Carboplatin Therapy. Med Sci Monit (2017) 0.75
Effects of a self-management program on antiemetic-induced constipation during chemotherapy among breast cancer patients: a randomized controlled clinical trial. Breast Cancer Res Treat (2015) 0.75
Efficacy analysis of the aprepitant-combined antiemetic prophylaxis for non-round cell soft-tissue sarcoma patients received adriamycin and ifosfamide therapy. Medicine (Baltimore) (2016) 0.75
Evaluating the antiemetic administration consistency to prevent chemotherapy-induced nausea and vomiting with the standard guidelines: a prospective observational study. Ther Clin Risk Manag (2017) 0.75
MASCC/ESMO Antiemetic Guidelines: Introduction to the 2016 guideline update. Support Care Cancer (2016) 0.75
Longitudinal perceptions of the side effects of chemotherapy in patients with gynecological cancer. Support Care Cancer (2017) 0.75
Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol (2001) 11.35
Current concepts of the immunological function of the thymus. Physiol Rev (1967) 8.37
Changes in physicians' attitudes toward telling the cancer patient. JAMA (1979) 7.75
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol (1996) 7.02
The influence of margin width on local control of ductal carcinoma in situ of the breast. N Engl J Med (1999) 6.16
Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol (2010) 5.96
The prevalence of psychiatric disorders among cancer patients. JAMA (1983) 5.48
A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer (2000) 4.96
Increased cholecystectomy rate after the introduction of laparoscopic cholecystectomy. JAMA (1993) 4.50
Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med (1994) 4.34
Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res (2000) 3.75
Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res (2000) 3.42
Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol (2001) 3.06
Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol (1997) 2.96
ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol (2001) 2.87
Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose. Eur J Cancer (2004) 2.73
A long-term follow-up study of survival in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma. J Clin Oncol (1989) 2.71
Recommendations on health-related quality of life research to support labeling and promotional claims in the United States. Qual Life Res (2000) 2.65
Detection of the anti-Hu antibody in the serum of patients with small cell lung cancer--a quantitative western blot analysis. Ann Neurol (1990) 2.58
Surveillance scanning of children with medulloblastoma. N Engl J Med (1994) 2.47
Kaposi's sarcoma in recipients of renal transplants. Am J Med (1979) 2.45
Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study. J Clin Oncol (1993) 2.42
American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel. J Clin Oncol (2000) 2.39
Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol (2005) 2.34
ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol (1998) 2.26
Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy? Ann Oncol (2008) 2.26
Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. J Clin Oncol (1996) 2.21
Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol (1997) 2.19
Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group. N Engl J Med (1999) 2.18
Mortality and cardiovascular disease among older live kidney donors. Am J Transplant (2014) 2.16
Susceptibility of nonpromoter CpG islands to de novo methylation in normal and neoplastic cells. J Natl Cancer Inst (2001) 2.13
Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. J Natl Cancer Inst (1995) 2.10
Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer. J Natl Cancer Inst (1998) 2.07
American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol (1999) 2.03
A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer (2004) 2.01
Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. Ann Oncol (2000) 2.00
Paclitaxel and cardiotoxicity. J Clin Oncol (1998) 1.99
Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol (1997) 1.97
Diagnostic and prognostic value of [(18)F]fluorodeoxyglucose positron emission tomography for recurrent head and neck squamous cell carcinoma. J Clin Oncol (2002) 1.96
Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J (2001) 1.93
p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am J Pathol (1993) 1.85
Quality of life in oncology practice: prognostic value of EORTC QLQ-C30 scores in patients with advanced malignancy. Eur J Cancer (1997) 1.85
Who keeps the first outpatient appointment? Am J Psychiatry (1981) 1.84
Factors influencing prognosis in node-negative breast carcinoma: analysis of 767 T1N0M0/T2N0M0 patients with long-term follow-up. J Clin Oncol (1993) 1.83
The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol (1991) 1.81
Methodology in behavioral and psychosocial cancer research. The assessment of nausea and vomiting. Past problems, current issues and suggestions for future research. Cancer (1984) 1.80
The effects of thymus and other lymphoid organs enclosed in millipore diffusion chambers on neonatally thymectomized mice. J Exp Med (1965) 1.78
Proliferation measurements with flow cytometry Tpot in cancer of the uterine cervix: correlation between two laboratories and preliminary clinical results. Int J Radiat Oncol Biol Phys (1995) 1.77
Ras oncogene point mutation: an infrequent event in bronchioloalveolar cancer. J Thorac Cardiovasc Surg (1992) 1.72
Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol (1985) 1.72
A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res (2001) 1.72
Detailed quality of life assessment in patients treated with primary radiotherapy for squamous cell cancer of the base of the tongue. Head Neck (1997) 1.71
DNA methylation profiles in diffuse large B-cell lymphoma and their relationship to gene expression status. Leukemia (2008) 1.70
High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil. Clin Cancer Res (1998) 1.68
Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. Cancer Res (1998) 1.65
Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small-cell lung cancer treated with combination chemotherapy. J Clin Oncol (1986) 1.63
Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group. J Clin Oncol (1999) 1.63
Guidelines for reporting results of quality of life assessments in clinical trials. Qual Life Res (1996) 1.58
Prevalence and correlates of anticipatory nausea and vomiting in chemotherapy patients. J Natl Cancer Inst (1982) 1.58
Pathological prognostic factors in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma: a study of 644 patients with median follow-up of 18 years. J Clin Oncol (1989) 1.57
Restriction of the capacity to respond to two antigens by single precursors of antibody-producing cells in culture. J Exp Med (1969) 1.55
Quality-of-life assessment: patient compliance with questionnaire completion. J Natl Cancer Inst (1992) 1.55
Some physical and radiobiological properties of immunologically reactive mouse spleen cells. J Exp Med (1970) 1.55
Genetic analysis as an aid in diagnosis for patients with midline carcinomas of uncertain histologies. J Natl Cancer Inst (1991) 1.55
Pulse oximetry and factors associated with hemoglobin oxygen desaturation in children with sickle cell disease. Blood (1993) 1.54
Quality of life scores: an independent prognostic variable in a general population of cancer patients receiving chemotherapy. The National Cancer Institute of Canada Clinical Trials Group. Qual Life Res (1997) 1.54
American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene. J Clin Oncol (1999) 1.52
Contribution of dexamethasone to control of chemotherapy-induced nausea and vomiting: a meta-analysis of randomized evidence. J Clin Oncol (2000) 1.50
Single-agent chemotherapy trials in small-cell lung cancer, 1970 to 1990: the case for studies in previously treated patients. J Clin Oncol (1992) 1.49
Morbidity and mortality after neoadjuvant therapy for lung cancer: the risks of right pneumonectomy. Ann Thorac Surg (2001) 1.49
Pharyngeal reflux after gastric pull-up esophagectomy with neck and chest anastomoses. J Thorac Cardiovasc Surg (1999) 1.48
Definition of histopathologic changes in gastroesophageal reflux disease. Am J Surg Pathol (2000) 1.47
Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy. Cancer Res (1998) 1.45
Serum erythropoietin titers in patients with human immunodeficiency virus (HIV) infection and anemia. J Acquir Immune Defic Syndr (1991) 1.45
Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. J Natl Cancer Inst (2000) 1.45
Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression. J Natl Cancer Inst (1997) 1.45
2000 update of American Society of Clinical Oncology colorectal cancer surveillance guidelines. J Clin Oncol (2000) 1.43
Comparative study of infectious complications of different types of chronic central venous access devices. Cancer (1994) 1.41
Factors associated with complications in microvascular reconstruction of head and neck defects. Plast Reconstr Surg (1999) 1.40
Poland's syndrome: a mammographic presentation. AJR Am J Roentgenol (1996) 1.40
Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin. J Clin Oncol (1989) 1.39
Recommended colorectal cancer surveillance guidelines by the American Society of Clinical Oncology. J Clin Oncol (1999) 1.39
Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer. A multicenter, randomized clinical trial by the National Cancer Institute of Canada. Ann Intern Med (1987) 1.38
How readable are subject consent forms? JAMA (1980) 1.38
Indications for lower urinary tract reconstruction in women after cystectomy for bladder cancer: a pathological review of female cystectomy specimens. J Urol (1995) 1.38
Transitional cell carcinoma involving the prostate with a proposed staging classification for stromal invasion. J Urol (1996) 1.37
The use of significant others as proxy raters of the quality of life of patients with brain cancer. Med Care (1997) 1.37
p53 and treatment of bladder cancer. Nature (1997) 1.36
Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: a University of Rochester Cancer Center Community Clinical Oncology Program study. Ann Intern Med (2000) 1.35
Initial clinical trial of a selective retinoid X receptor ligand, LGD1069. J Clin Oncol (1997) 1.34
Contralateral breast carcinoma: an assessment of risk and prognosis in stage I (T1N0M0) and stage II (T1N1M0) patients with 20-year follow-up. Surgery (1989) 1.34
p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: an analysis of response and survival. Clin Cancer Res (1998) 1.32
Canadian multicenter randomized trial comparing sequential and alternating administration of two non-cross-resistant chemotherapy combinations in patients with limited small-cell carcinoma of the lung. J Clin Oncol (1987) 1.31
Patient expectations as predictor of chemotherapy-induced nausea. Ann Behav Med (2000) 1.31
Patients' experiences using a computerized program with a touch-sensitive video monitor for the assessment of health-related quality of life. Qual Life Res (1998) 1.31